Onconaut Therapeutics

Executive Summary

Onconaut Therapeutics is a preclinical-stage biotechnology company developing first-in-class small molecule inhibitors targeting CHD1L, a novel oncogene implicated in cancer progression, metastasis, and drug resistance across multiple solid tumors including liver, breast, lung, and colon cancers. Founded in 2022 and headquartered in San Diego, the company aims to address significant unmet medical needs by validating CHD1L as a druggable target and advancing a lead candidate toward clinical development. CHD1L overexpression is associated with poor prognosis and resistance to standard therapies, making it a promising target for patients with limited treatment options. Onconaut's approach leverages structure-based drug design and phenotypic screening to identify potent and selective inhibitors with favorable drug-like properties.

Upcoming Catalysts (preview)

• Q3 2026Preclinical in vivo efficacy data for lead CHD1L inhibitor60% success
• H2 2026Series A financing round close70% success
• Q4 2026IND-enabling studies initiation40% success